| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.metropolisindia.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 15,315.86 Cr. | |
| Earnings per share (EPS) | 35.79 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 83.65 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 202.10 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 136.63 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 21.91 | Calculated using Price: 2,994.05 |
| Dividend Yield | 0.27 | Period Ending 2021-03 |
| No. of Shares Subscribed | 5.12 Cr. | 51,154,329 Shares |
| FaceValue | 2 | |
| Company Profile | ||
|
Metropolis Healthcare Limited is one of leading and renowned Indian diagnostics companies. The company owns a chain of diagnostic ce9ntres across India, South Asia, Africa and the Middle East. Over the years, Metropolis has carved a niche for itself. The company enjoys a loyal customer base, reflecting its strength as a brand offering superior diagnostic tests and services. With its widespread operational network, Metropolis offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis plays a pivotal role in raising the bar of diagnostic accuracy, technological equipment, customer experience and research-driven empathetic service in the industry. Business area of the company Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It classifies its tests into ‘routine’ tests such as blood chemistry analyses, blood cell counts and urine examination; ‘semi-specialized’ tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and ‘specialized’ tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics. It is focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports. It also offers customized wellness packages to its institutional customers as per their requirement. Services
Awards FY2018-19
FY2019-20
Major Events & Milestones
|
||
Company Profile
Metropolis Healthcare Limited is one of leading and renowned Indian diagnostics companies. The company owns a chain of diagnostic ce9ntres across India, South Asia, Africa and the Middle East. Over the years, Metropolis has carved a niche for itself. The company enjoys a loyal customer base, reflecting its strength as a brand offering superior diagnostic tests and services.
With its widespread operational network, Metropolis offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis plays a pivotal role in raising the bar of diagnostic accuracy, technological equipment, customer experience and research-driven empathetic service in the industry.
Business area of the company
Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It classifies its tests into ‘routine’ tests such as blood chemistry analyses, blood cell counts and urine examination; ‘semi-specialized’ tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and ‘specialized’ tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics. It is focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports. It also offers customized wellness packages to its institutional customers as per their requirement.
Services
Awards
FY2018-19
FY2019-20
Major Events & Milestones
| 1 Day |
|
+0.28% |
| 1 Week |
|
-2.56% |
| 1 Month |
|
+1.45% |
| 3 Month |
|
+29.39% |
| 6 Month |
|
+38.50% |
| 1 Year |
|
+83.24% |
| 2 Year |
|
+193.33% |
| 5 Year |
|
| 7 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 18.77 | 26.16 | 36.47 | 30.38 | 30.17 | 27.33 | 30.07 | |
| Return on Capital Employed (%) | 27.47 | 40.06 | 54.28 | 45.22 | 45.10 | 37.90 | 41.60 | |
| Return on Assets (%) | 14.48 | 19.06 | 23.75 | 16.93 | 15.51 | 14.78 | 18.43 |
| Particulars | 7 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 361 | 265 | 323 | 415 | 419 | 524 | 707 | |
| Non Curr. Liab. | 10 | 1 | 16 | 148 | 142 | 195 | 111 | |
| Curr. Liab. | 75 | 105 | 152 | 233 | 241 | 210 | 240 | |
| Minority Int. | 23 | 20 | 21 | 14 | 1 | 2 | 1 | |
| Equity & Liab. | 468 | 391 | 512 | 810 | 803 | 930 | 1,059 | |
| Non Curr. Assets | 167 | 166 | 227 | 367 | 381 | 492 | 415 | |
| Curr. Assets | 302 | 225 | 285 | 443 | 422 | 438 | 645 | |
| Misc. Exp. not W/O | ||||||||
| Total Assets | 468 | 391 | 512 | 810 | 803 | 930 | 1,059 |
| Particulars | 7 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 455 | 524 | 545 | 647 | 761 | 856 | 998 | |
| Other Income | 6 | 22 | 26 | 8 | 8 | 9 | 12 | |
| Total Income | 461 | 546 | 570 | 655 | 769 | 865 | 1,010 | |
| Total Expenditure | -337 | -388 | -391 | -469 | -557 | -619 | -708 | |
| PBIDT | 124 | 158 | 179 | 186 | 212 | 246 | 302 | |
| Interest | -2 | -2 | -2 | -4 | -4 | -13 | -12 | |
| Depreciation | -21 | -21 | -17 | -19 | -20 | -39 | -46 | |
| Taxation | -33 | -46 | -53 | -52 | -63 | -41 | -61 | |
| Exceptional Items | -8 | -25 | ||||||
| PAT | 68 | 82 | 107 | 112 | 125 | 128 | 183 |
| Particulars | 5 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 102 | 104 | 90 | 215 | 249 | |
| Cash Fr. Inv. | -86 | 2 | 35 | -105 | 62 | |
| Cash Fr. Finan. | -17 | -87 | -118 | -55 | -33 | |
| Net Change | -1 | 19 | 7 | 55 | 278 | |
| Cash & Cash Eqvt | 26 | 43 | 51 | 107 | 387 |
|
Mon, 02 Aug 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation We would like to inform you that Edelweiss Broking Limited will host an Earnings call on behalf of the Company with the analysts and investors at 5:30 p.m. (IST) on Friday August 6 2021 wherein the management of the Company will discuss the Financial and Operational Performance of Q1FY22. This is for your information and appropriate dissemination. |
|
Sat, 31 Jul 2021
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On Friday August 6 2021 Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended June 30 2021; Proposal for raising funds either by way of private placement or preferential issue or public issue or through any other permissible mode and/or combination thereof including by way of Qualified Institutions Placement in accordance with applicable laws; and other matters |
|
Mon, 19 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication Copy of Newspaper Publication |
| Wed, 04 Aug 2021 |
Closing Above Previous High
|
Close Within 52 Week High Zone
|
| Tue, 03 Aug 2021 |
|
Close Within 52 Week High Zone
|
Increasing Relative Strength - Sectoral Index
|
MFI Trending Up
|
Equities
M.F.
Sectors